25 Ovarian Cancer Clinical Trials in Boston, NY (2026)

Q: How do I join a clinical trial in Boston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you.

Recruiting Ovarian Cancer Studies in Boston

NCT03564340Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of...

Boston, NY890 participantsRegeneron Pharmaceuticals

View Study Details

NCT05349227Recruiting

Comprehensive Outcomes for After Cancer Health

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to...

Boston, NY625 participantsPack Health

View Study Details

NCT04590326Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as RE...

Boston, NY612 participantsRegeneron Pharmaceuticals

View Study Details

NCT04575935Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherap...

Boston, NY580 participantsM.D. Anderson Cancer Center

View Study Details

NCT06843447Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickl...

Boston, NY460 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05470920Recruiting

Genetic Testing Decision Aid

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancr...

Boston, NY350 participantsMassachusetts General Hospital

View Study Details

NCT06234423Recruiting

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors....

Boston, NY263 participantsOnCusp Therapeutics, Inc.

View Study Details

NCT04794322Recruiting

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples...

Boston, NY250 participantsMassachusetts General Hospital

View Study Details

NCT07213791Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation prote...

Boston, NY241 participantsEli Lilly and Company

View Study Details

NCT06710548Recruiting

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibito...

Boston, NY240 participantsDana-Farber Cancer Institute

View Study Details

NCT06515613Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participan...

Boston, NY156 participantsContext Therapeutics Inc.

View Study Details

NCT06774963Recruiting

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 i...

Boston, NY145 participantsNextCure, Inc.

View Study Details

NCT06543537Recruiting

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda...

Boston, NY112 participantsDana-Farber Cancer Institute

View Study Details

NCT05287451Recruiting

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade ser...

Boston, NY100 participantsM.D. Anderson Cancer Center

View Study Details

NCT07226427Recruiting

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 mono...

Boston, NY100 participantsStemline Therapeutics, Inc.

View Study Details

NCT07303894Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be c...

Boston, NY90 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06469281Recruiting

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with ...

Boston, NY90 participantsRegeneron Pharmaceuticals

View Study Details

NCT06888921Recruiting

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also l...

Boston, NY60 participantsCompugen Ltd

View Study Details

NCT03877796Recruiting

Clinical Pre-screening Protocol for Ovarian Cancer

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be lik...

Boston, NY60 participantsAllarity Therapeutics

View Study Details

NCT04641247Recruiting

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment wit...

Boston, NY37 participantsGlaxoSmithKline

View Study Details

NCT06677190Recruiting

Belzutifan in Recurrent Clear Cell Ovarian Carcinoma

The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer. The name of the study drug involved in this study is: \- Belzuti...

Boston, NY32 participantsDana-Farber Cancer Institute

View Study Details

NCT06964009Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. T...

Boston, NY30 participantsElizabeth Stover, MD, PhD

View Study Details

NCT04997096Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ...

Boston, NY30 participantsDana-Farber Cancer Institute

View Study Details

NCT04701645Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, an...

Boston, NY20 participantsBrigham and Women's Hospital

View Study Details

NCT06321484Recruiting

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (...

Boston, NY18 participantsDana-Farber Cancer Institute

View Study Details

About Ovarian Cancer Clinical Trials in Boston

Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.

There are currently 25 ovarian cancer clinical trials recruiting participants in Boston, NY. These studies are seeking a combined 5,591 participants. Research is being sponsored by Regeneron Pharmaceuticals, Pack Health, M.D. Anderson Cancer Center and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ovarian Cancer Clinical Trials in Boston — FAQ

Are there ovarian cancer clinical trials in Boston?

Yes, there are 25 ovarian cancer clinical trials currently recruiting in Boston, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What ovarian cancer treatments are being tested?

The 25 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.

Data updated July 13, 2026 from ClinicalTrials.gov